Phase 1 N=50 Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
Vaccine
Primary: Safety Events — 20; 0; 40; 50 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=66 Phase 1 Study for IPG11406 in Health Volunteer
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
Phase 1 N=24 A Safety Study of PTI-125 in Healthy Volunteers
Alzheimer Disease, Early Onset · Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 315; NA; 550; NA ng/mL
Phase 1 N=24 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
Phase 1 N=16 Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
Healthy Volunteers
Primary: Incidence of Abnormal Physical Exam Findings — 0; 0; 0 Participants
Phase 1 N=41 A Study of OsrHSA in Adult Healthy Male and Female Volunteers
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Phase 1 N=8 First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367
Malaria,Falciparum
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) — 1; 4; 5; 1 Number of events
Phase 1 N=60 Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
Chikungunya Virus
Primary: Part A: Number of Participants With Any Solicited Adverse Events (AEs) (Local and Systemic Reactogenicity Events) — 11; 10; 11; 10 Participants
Phase 1 N=25 A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
Safety and Tolerability
Primary: Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions — 1; 2; 3; 2 Participants
N/A N=206 Safety Follow-Up to HP 802-247-09-015
Venous Leg Ulcer · Venous Stasis Ulcer
Primary: The Number of Participants With Closed Target Ulcers at Each Visit — 27; 21; 25; 23 participants
Phase 1 N=12 A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
Respiratory Syncytial Viruses
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants
N/A N=13 Clinical Trial Testing the BioSerenity Pulse Oximeter (EOXY) Efficacy, Performance and Safety in Healthy Volunteer
Healthy
Primary: Percentage SPO2 Accuracy Root-Mean Square (ARMS) at Forehead Position — 3.91; 3.08; 3.36; 2.85 percentage of ARMS (accuracy)
Phase 1 N=36 A Safety Study of AZD4041 in Healthy Participants
Opioid Use Disorder (OUD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 8; 6; 6; 9 Participants
Phase 1 N=21 Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
Campylobacter Jejuni Infection
Primary: Count of Participants With Adverse Events — 0; 1; 3; 1 Participants
N/A N=31 A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects
Healthy
Primary: Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) — 21.48 U/L
Phase 1 N=130 COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers
Coronavirus
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events — 7; 2; 0; 3 Participants
Phase 1 N=244 Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer
Health, Subjective
Primary: Incidence Rate of Drug Allergy Following ID Injection of the IP — 0; 0; 1; 0 Participants
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=24 Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
Covid19
Primary: Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax]) — 57.2; 41.7; 46.5; 22.3 ng/mL — p=0.803
N/A N=18 Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects
Healthy
Primary: Performance: EEG Recordings - Impedance — 2.3 Impedance (kOhm)
Phase 1 N=26 VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
Phase 1 N=60 Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169
Healthy Subjects
Primary: Number of Adverse Events — 9; 4; 5; 2 AEs
Phase 1 N=29 A Study of LY3031207 in Healthy Subjects
Healthy Volunteers
Primary: Number of Participants With 1 or More Drug Related Adverse Events (AE) or Any Serious AE — 0; 0; 0; 0 Participants
N/A N=27 Novel Non-Invasive Monitoring Parameter in Healthy Volunteers
No Conditions · Focus is Respiratory Rate
Primary: The Covidien Nellcor Respiration Rate Software Shall Determine Respiration Rate Measured as Mean and Standard Deviation With Accuracy That is Non-inferior to Predicate…
Phase 1 N=18 A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants
Healthy
Primary: Maximum Serum Concentration(Cmax) for PF-06823859 — 307.4 micrograms/milliliter (ug/mL)
Phase 1 N=12 A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
Pharmacokinetics · Healthy Volunteers
Primary: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Rosuvastatin in Period 1 and 2 — 58.62; 72.78 Nanogram*hour per milliliter
Phase 1 N=20 BI 409306 Cardiac Safety Trial in Healthy Volunteers
Healthy
Primary: Slope of the Placebo-corrected Change From Baseline of Heart Rate at Rest and Plasma Concentration Between 0 to 10 Hours — 0.80; 5.46 beats/min
Phase 1 N=48 Cardiac Safety Evaluation of P03277
Healthy Volunteers
Primary: Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF) — 0.97; 5.05; 0.24; -0.11 milliseconds
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
N/A N=24 Healthy Adult Volunteer Study of Intraosseous Infusion Using the Sternum
Intraosseous Vascular Access
Primary: Occurrences of Extravasation During Infusion — 2 participants